Kissei Pharmaceutical Co (JP:4547) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Kissei Pharmaceutical Co. has entered into a research collaboration with Reborna Biosciences to develop treatments for genetic rare diseases, using Reborna’s RNA-targeting technology. Kissei will handle development and commercialization, providing payments including milestones and royalties to Reborna. This partnership aims to leverage both companies’ strengths to address challenges in rare disease drug discovery.
For further insights into JP:4547 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue